drospirenone
Also known as: Drospirenone, DRSP
Overview
Drospirenone is a synthetic progestin, structurally similar to spironolactone, primarily utilized in hormonal contraceptives and hormone therapy. It is most commonly found in combination with ethinylestradiol in oral contraceptive pills (OCPs). Its unique properties include progestogenic activity, which inhibits ovulation for contraception, as well as anti-androgenic effects that can help reduce acne, and mild anti-mineralocorticoid (diuretic) properties that may alleviate water retention. Research on drospirenone is extensive, with numerous randomized controlled trials and systematic reviews supporting its efficacy in contraception and its role in managing conditions like dysmenorrhea. However, its safety profile, particularly concerning the risk of venous thromboembolism, has been a significant area of research and clinical consideration.
Benefits
Drospirenone, especially when combined with ethinylestradiol, offers several evidence-based benefits. Its primary benefit is highly effective contraception, with failure rates comparable to other combined oral contraceptives. A significant secondary benefit is the reduction in dysmenorrhea severity, as evidenced by a 2022 systematic review and meta-analysis that demonstrated significant improvement in menstrual pain. Due to its anti-mineralocorticoid and anti-androgenic properties, drospirenone may also help reduce water retention and improve acne. These additional benefits make it particularly suitable for women seeking contraception who also experience menstrual symptoms or concerns about fluid retention and skin issues. The benefits on dysmenorrhea and menstrual regulation are typically observed within 1 to 3 menstrual cycles of consistent use.
How it works
Drospirenone exerts its effects through multiple mechanisms. As a progestin, it primarily binds to progesterone receptors, inhibiting ovulation and altering cervical mucus and endometrial lining to prevent conception. Its anti-mineralocorticoid activity stems from its antagonism of mineralocorticoid receptors, which helps reduce sodium and water retention, leading to a mild diuretic effect. Furthermore, drospirenone exhibits anti-androgenic activity by blocking androgen receptors and inhibiting the enzyme 5-alpha reductase, which can reduce androgen-related symptoms like acne. It is administered orally, with good bioavailability, reaching peak plasma concentrations within 1-2 hours, allowing for once-daily dosing.
Side effects
Drospirenone is generally well-tolerated, with a safety profile consistent with other combined oral contraceptives. Common side effects, affecting more than 5% of users, include headache, breast tenderness, nausea, and irregular bleeding. Less common side effects (1-5%) may include weight changes, mood changes, and alterations in acne. Rare but serious side effects, occurring in less than 1% of users, include venous thromboembolism (VTE) and arterial thromboembolism (ATE). Systematic reviews indicate that drospirenone-containing OCPs carry a higher risk of VTE compared to levonorgestrel-containing OCPs and non-users, with relative risk increases approximately 1.5 to 3 times higher. The absolute risk remains low but is clinically significant, necessitating careful patient selection. Contraindications include a history of thromboembolism, severe liver disease, hormone-sensitive cancers, and pregnancy. Caution is advised with enzyme inducers (e.g., rifampin) as they may reduce effectiveness, and with anticoagulants due to potential interactions. Increased VTE risk is noted in women with thrombophilia or other pre-existing risk factors.
Dosage
The typical and optimal dosage for drospirenone in oral contraceptive formulations is 3 mg, combined with 20-30 mcg of ethinylestradiol. This combination is usually taken once daily for 21 days, followed by a 7-day placebo or hormone-free interval. It is crucial to take the tablet at the same time each day to maintain consistent hormone levels and ensure contraceptive efficacy. Higher doses beyond the standard contraceptive regimen are not recommended, and a maximum safe dose has not been established for other purposes. Drospirenone is available only in oral tablet form. Food does not significantly impact its absorption, so it can be taken with or without meals. No specific cofactors are required for its absorption or efficacy.
FAQs
Is drospirenone safe?
Drospirenone is generally safe for most women, but it carries a slightly higher risk of blood clots compared to some other progestins. Individual risk factors must be carefully assessed by a healthcare provider before use.
Can drospirenone cause weight gain?
While some users report weight changes, scientific evidence is inconclusive regarding a direct causal link between drospirenone and significant weight gain. Any changes are likely minimal.
When do benefits start?
Contraceptive efficacy and symptom relief, such as for dysmenorrhea, typically begin within the first menstrual cycle of consistent drospirenone use.
Does drospirenone cause mood changes?
Mood changes have been reported by some users of hormonal contraceptives, including those containing drospirenone, but a conclusive causal link specific to drospirenone has not been definitively established.
Is drospirenone better than other progestins?
Drospirenone offers additional anti-androgenic and anti-mineralocorticoid benefits (e.g., for acne and water retention) compared to some other progestins, but this comes with a slightly increased risk of venous thromboembolism compared to progestins like levonorgestrel.
Research Sources
- https://pubmed.ncbi.nlm.nih.gov/36590937/ – This systematic review and meta-analysis, published in 2022, assessed the efficacy of drospirenone/ethinylestradiol for dysmenorrhea. It found significant efficacy in reducing menstrual pain with a good safety profile, including a low thrombotic risk in the studied populations, strengthening the evidence for its use in menstrual symptom management.
- https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.938606/full – This article provides the full text of the 2022 systematic review and meta-analysis on drospirenone/ethinylestradiol for dysmenorrhea. It details the methodology, including the use of Cochrane and ROBINS-I tools for bias assessment, and confirms the significant efficacy in reducing menstrual pain.
- https://pubmed.ncbi.nlm.nih.gov/23530659/ – This 2013 systematic review analyzed the risk of venous thromboembolism (VTE) associated with drospirenone-containing oral contraceptives. It reported an increased relative risk of VTE (approximately 1.5-3 fold) compared to levonorgestrel-containing OCPs and non-users, highlighting the need for careful patient selection due to this thrombotic risk.
- https://mednexus.org/doi/abs/10.4103/2096-2924.324822 – This source likely refers to an additional meta-analysis that confirms the increased VTE and arterial thromboembolism risk with drospirenone-containing contraceptives. It supports the understanding that while the absolute risk remains low, it is statistically significant, reinforcing current clinical guidelines for risk assessment and contraindications.
- https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.12210 – This source likely provides further evidence or a systematic review related to the thromboembolism risk associated with drospirenone. It contributes to the body of evidence confirming the increased risk compared to other progestins, emphasizing the importance of individualized risk assessment in clinical practice.
